Emmaus Financial Statements From 2010 to 2026
| EMMA Stock | USD 0.01 0 20.37% |
Check Emmaus Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emmaus Life's main balance sheet or income statement drivers, such as , as well as many indicators such as . Emmaus financial statements analysis is a perfect complement when working with Emmaus Life Valuation or Volatility modules.
Emmaus |
Emmaus Life Sciences OTC Stock Current Valuation Analysis
Emmaus Life's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Emmaus Life Current Valuation | 49.41 M |
Most of Emmaus Life's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emmaus Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Emmaus Life Sciences has a Current Valuation of 49.41 M. This is 99.66% lower than that of the Pharmaceuticals sector and 98.94% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.7% higher than that of the company.
Emmaus Life Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Emmaus Life's current stock value. Our valuation model uses many indicators to compare Emmaus Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emmaus Life competition to find correlations between indicators driving Emmaus Life's intrinsic value. More Info.Emmaus Life Sciences is one of the top stocks in return on asset category among its peers. It is rated # 3 in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Emmaus Life by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Emmaus Life's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Emmaus Life Financial Statements
Emmaus Life stakeholders use historical fundamental indicators, such as Emmaus Life's revenue or net income, to determine how well the company is positioned to perform in the future. Although Emmaus Life investors may analyze each financial statement separately, they are all interrelated. For example, changes in Emmaus Life's assets and liabilities are reflected in the revenues and expenses on Emmaus Life's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Emmaus Life Sciences. Please read more on our technical analysis and fundamental analysis pages.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. Emmaus Life operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 58 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in Emmaus OTC Stock
Emmaus Life financial ratios help investors to determine whether Emmaus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emmaus with respect to the benefits of owning Emmaus Life security.